Cite
HARVARD Citation
Price, T. et al. (2019). Phase II APEC trial: The impact of primary tumor side on outcomes of first‐line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild‐type metastatic colorectal cancer. Asia-Pacific journal of clinical oncology. 15 (4), pp. 225-230. [Online].